$23.3Bn Antibody-Drug Conjugate Market Trends & Forecasts, 2035: 530+ Therapies, 140+ Developers The antibody-drug conjugate (ADC) market is poised for significant growth, with projections indicating an increase from USD 7.72 billion in the current year to USD 23.3 billion by…
MANSCAPED Unveils TCS Ball Hero Bundle for Testicular Cancer Awareness MANSCAPED, the global leader in men’s grooming, has built a reputation not only for its innovative grooming products and clever marketing but also for its commitment to a cause that…
Ono & Reborna Partner for CNS RNA-Targeting Drug Discovery Ono Pharmaceutical Co., Ltd. (Headquartered in Osaka, Japan; President and COO: Toichi Takino; hereafter referred to as “Ono”) has announced a strategic collaboration agreement with Reborna Biosciences, Inc. (Headquartered in Kanagawa,…
Novotech Secures Investment from GIC, Temasek, and TPG to Drive Global Expansion Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), has announced a significant investment from leading global investors GIC and Temasek. The two firms have signed…
Nosis Biosciences and Daiichi Sankyo Partner to Advance RNA Medicines Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, has announced a Research Collaboration and Option Agreement with Daiichi Sankyo. This collaboration aims to leverage…
Agenus Reports Q4 2024 Results, Strengthens BOT/BAL Program Agenus Reports Q4 and Full-Year 2024 Financial and Operational Results, Implements Strategic Cost Reductions to Enhance Sustainability of BOT/BAL Program Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), a leading immuno-oncology company…
RoslinCT and Ayrmid Pharma Ltd. Plan Strategic Partnership for Omisirge® Manufacturing Ayrmid Pharma Ltd., a pioneering company in cell therapy focused on transforming cells into powerful therapeutics, and RoslinCT, a world-leading contract development and manufacturing organization (CDMO) specializing in cell…
bioAffinity Cuts $4M in Costs to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company dedicated to advancing noninvasive diagnostic solutions for early-stage lung cancer and other respiratory diseases, has announced a series of strategic actions…
Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, has announced its financial…
Tenovi and GenieMD Partner to Revolutionize Remote Care and Improve Medication Adherence GenieMD and Tenovi have announced a groundbreaking partnership aimed at expanding access to remote care and improving medication adherence through transformative virtual healthcare solutions. By integrating Tenovi’s FDA-cleared…
Repare Therapeutics Shares Business, Clinical Update & 2024 Financial Results Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, has released its financial results for the fourth quarter and full year ending December 31, 2024.…
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings SmithRx, a transparent and fully pass-through modern pharmacy benefits manager (PBM), has announced a significant expansion of its Connect 360 Autoimmune Program. This initiative includes the introduction of Stelara biosimilars, new low-cost Humira…
